Background Apart from allergic mechanisms, a lack or mutation of metabolic enzymes may
cause adverse drug reactions. Patch testing has rarely been useful in cutaneous adverse …

Objective This study aimed to describe the genetic and clinical risk factors associated with
phenytoin‐induced cutaneous adverse drug reactions (PHT‐induced cADRs) in Thai …

Importance The antiepileptic drug phenytoin can cause cutaneous adverse reactions,
ranging from maculopapular exanthema to severe cutaneous adverse reactions, which …

Background Aromatic anticonvulsant–induced severe cutaneous adverse drug reactions
(SCAR s), including S tevens–J ohnson syndrome (SJS), toxic epidermal necrosis (TEN) …

Although aromatic anticonvulsants are usually well tolerated, they can cause cutaneous
adverse drug reactions in up to 10% of patients. The clinical manifestations of the …

Purpose The purpose of this study was to investigate the association of genetic factors
including variants in HLA-B and CYP2C genes and non-genetic factors with phenotype …

Introduction Phenytoin is a frequently used drug treatment for epilepsy. Genetic
polymorphisms in the metabolism of phenytoin, particularly CYP2C9, are strongly …

CYP2C9 is the key enzyme in aromatic antiepileptic drugs (AEDs) metabolism. CYP2C9* 3
is a loss of function polymorphism. This study was designed to investigate genetic …

To develop a pre‐emptive genetic test that comprises multiple predisposing alleles for the
prevention of phenytoin‐related severe cutaneous adverse reactions (SCARs), three sets of …

Objective Many commonly used pharmaceuticals, such as antidepressants and neuroleptics
as well as some illegal drugs, are metabolised by the cytochrome P 450 enzyme …